Retatrutide, a novel dual stimulator of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) binding site , is demonstrating promising outcomes in early clinical studies. Ongoing https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/